Abstract
Alefacept is a fully human fusion protein for use in adult patients with moderate to severe chronic plaque psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. We report the clinical course of two patients with hepatitis C virus (HCV) infection who have received alefacept for psoriasis. Consistent with its mechanism of action, administration of alefacept led to transient decreases in CD4+ and CD8+ T-cell counts. However, these reductions were not associated with an increase in HCV viral load or exacerbation of infection. Liver enzymes remained stable throughout the treatment and follow-up periods. Alefacept has a selective mechanism of action that specifically targets memory T cells and this selectivity may account for its safety and tolerability in patients with hepatitis.
| Original language | English |
|---|---|
| Journal | British Journal of Dermatology |
| Volume | 152 |
| Issue number | 5 |
| Pages (from-to) | 1048-1050 |
| Number of pages | 3 |
| ISSN | 0007-0963 |
| DOIs | |
| Publication status | Published - 05.2005 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
